Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Cost of Revenue (2021 - 2025)

BridgeBio Pharma's Cost of Revenue history spans 5 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 289.01% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $21.0 million, up 440.54%, while the annual FY2025 figure was $21.0 million, 440.54% up from the prior year.
  • Cost of Revenue for Q4 2025 was $8.1 million at BridgeBio Pharma, up from $6.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.1 million in Q4 2025 and bottomed at $109000.0 in Q2 2021.
  • The 5-year median for Cost of Revenue is $649000.0 (2022), against an average of $1.9 million.
  • The largest annual shift saw Cost of Revenue crashed 58.28% in 2022 before it surged 997.49% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $1.6 million in 2021, then plummeted by 58.28% to $647000.0 in 2022, then fell by 7.57% to $598000.0 in 2023, then surged by 248.49% to $2.1 million in 2024, then soared by 289.01% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Cost of Revenue are $8.1 million (Q4 2025), $6.6 million (Q3 2025), and $3.7 million (Q2 2025).